Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(07): 542-548
DOI: 10.1055/a-0978-4972
Article

Safety and Efficacy of Placenta-Derived Mesenchymal Stem Cell Treatment for Diabetic Patients with Critical Limb Ischemia: A Pilot Study

Jiao Wang‡
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, P.R. China
,
Xiang-Xia Zeng‡
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, P.R. China
,
Wei Cai
2   Department of Medical Genetics and Cell biology, Medical College of Nanchang University, Nanchang, P.R. China
,
Zhi-Bo Han
3   The Stem Cell Engineering Research Center of Jiangxi Province, Shangrao, P.R. China
,
Ling-Yan Zhu
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, P.R. China
,
Jian-Ying Liu
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, P.R. China
,
Ji-Xiong Xu
1   Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, P.R. China
› Author Affiliations Funding: Support was provided by grants from Jiangxi Provincial Science Technology Foundation of China (No.20151BBG70073) and the National Natural Science Funds of China (Nos. 81760168, 81560154 and 81460018).
› Further Information
Also available at
   Buy Article Permissions and Reprints

Abstract

Aim Diabetic foot has become the main cause of non-traumatic amputation. Stem cell therapy, especially mesenchymal stem cells (MSCs), holds a great promise as a therapy for diabetic foot with ischemia limb arterial disease. The aim of this pilot study is to evaluate the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment for diabetic patients with critical limb ischemia (CLI).

Methods Four eligible diabetic patients with CLI were consecutively enrolled in this pilot study. On the base of the standard-of-care treatment, these patients accepted P-MSCs treatment by intramuscular injection for successive 3 times at an interval of 4 weeks, and the safety and efficacy of placenta-derived MSCs (P-MSCs) treatment were evaluated.

Results There were no serious adverse events during the period of P-MSCs injection and the 24-weeks follow-up period. The clinical ischemic features of patients were improved 24 weeks after P-MSCs treatment. The scores of resting pain and limb coldness significantly decreased, and pain-free walking distance significantly increased from baseline to 24 weeks after P-MSCs therapy. The resting ankle brachial index increased, but no statistically significant difference was found. The findings of magnetic resonance angiography showed the increase of collateral vessel formation in one patient, but there were no significant changes observed in the other patients.

Conclusions The data in this pilot study indicated that multiple intramuscular P-MSCs injections may be a safe and effective alternative therapy for diabetic patients with CLI, and larger, placebo-controlled, perspective studies are needed to prove these results.

Key words

critical limb ischemia - diabetic foot - placenta-derived mesenchymal stem cell - cell therapy

Supplementary Material



Publication History

Received: 23 May 2019
Received: 23 May 2019

Accepted: 17 July 2019

Article published online:
14 August 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Boyko EJ, Seelig AD, Ahroni JH. Limb- and person-level risk factors for lower-limb amputation in the prospective seattle diabetic foot study. Diabetes Care 2018; 41: 891-898
    CrossrefPubMedGoogle Scholar
  • 2 Morbach S, Furchert H, Groblinghoff U. et al. Long-term prognosis of diabetic foot patients and their limbs: Amputation and death over the course of a decade. Diabetes Care 2012; 35: 2021-2027
    CrossrefPubMedGoogle Scholar
  • 3 Almasri J, Adusumalli J, Asi N. et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Journal of Vascular Surgery 2018; 68: 624-633
    CrossrefPubMedGoogle Scholar
  • 4 Patel SD, Biasi L, Paraskevopoulos I. et al. Comparison of angioplasty and bypass surgery for critical limb ischaemia in patients with infrapopliteal peripheral artery disease. The British Journal of Surgery 2016; 103: 1815-1822
    CrossrefPubMedGoogle Scholar
  • 5 Teraa M, Conte MS, Moll FL. et al. Critical limb ischemia: Current trends and future directions. Journal of the American Heart Association 2016; 5: e002938
    CrossrefPubMedGoogle Scholar
  • 6 Tateishi-Yuyama E, Matsubara H, Murohara T. et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet (London, England) 2002; 360: 427-435
    CrossrefPubMedGoogle Scholar
  • 7 Xie B, Luo H, Zhang Y. et al. Autologous stem cell therapy in critical limb ischemia: A meta-analysis of randomized controlled trials. Stem Cells International 2018; 2018: 7528464
    PubMedGoogle Scholar
  • 8 Liang L, Li Z, Ma T. et al. Transplantation of human placenta-derived mesenchymal stem cells alleviates critical limb ischemia in diabetic nude rats. Cell Transplant 2017; 26: 45-61
    CrossrefPubMedGoogle Scholar
  • 9 Zeng X, Tang Y, Hu K. et al. Three-week topical treatment with placenta-derived mesenchymal stem cells hydrogel in a patient with diabetic foot ulcer: A case report. Medicine 2017; 96: e9212
    CrossrefPubMedGoogle Scholar
  • 10 Jiang R, Han Z, Zhuo G. et al. Transplantation of placenta-derived mesenchymal stem cells in type 2. diabetes: A pilot study. Frontiers of Medicine 2011; 5: 94-100
    PubMedGoogle Scholar
  • 11 Brooke G, Rossetti T, Pelekanos R. et al. Manufacturing of human placenta-derived mesenchymal stem cells for clinical trials. British Journal of Haematology 2009; 144: 571-579
    CrossrefPubMedGoogle Scholar
  • 12 Qin HL, Zhu XH, Zhang B. et al. Clinical evaluation of human umbilical cord mesenchymal stem cell transplantation after angioplasty for diabetic foot. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2016; 124: 497-503
    PubMedGoogle Scholar
  • 13 Cai J, Wu Z, Xu X. et al. Umbilical cord mesenchymal stromal cell with autologous bone marrow cell transplantation in established type 1 diabetes: A pilot randomized controlled open-label clinical study to assess safety and impact on insulin secretion. Diabetes care 2016; 39: 149-157
    CrossrefPubMedGoogle Scholar
  • 14 Carlsson PO, Schwarcz E, Korsgren O. et al. Preserved beta-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015; 64: 587-592
    CrossrefPubMedGoogle Scholar
  • 15 Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. The Journal of Thoracic and Cardiovascular Surgery 2012; 144: 377-382
    CrossrefPubMedGoogle Scholar
  • 16 Das AK, Bin Abdullah BJ, Dhillon SS. et al. Intra-arterial allogeneic mesenchymal stem cells for critical limb ischemia are safe and efficacious: Report of a phase I study. World J Surg 2013; 37: 915-922
    CrossrefPubMedGoogle Scholar
  • 17 Lee HC, An SG, Lee HW. et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: A pilot study. Circulation Journal: Official Journal of the Japanese Circulation Society 2012; 76: 1750-1760
    CrossrefPubMedGoogle Scholar
  • 18 Komaki M, Numata Y, Morioka C. et al. Exosomes of human placenta-derived mesenchymal stem cells stimulate angiogenesis. Stem Cell Res Ther 2017; 8: 219
    CrossrefPubMedGoogle Scholar
  • 19 Xie N, Li Z, Adesanya TM. et al. Transplantation of placenta-derived mesenchymal stem cells enhances angiogenesis after ischemic limb injury in mice. Journal of Cellular and Molecular Medicine 2016; 20: 29-37
    CrossrefPubMedGoogle Scholar
  • 20 Du L, Lv R, Yang X. et al. Hypoxia enhances the protective effects of placenta-derived mesenchymal stem cells against scar formation through hypoxia-inducible factor-1alpha. Biotechnology Letters 2016; 38: 931-939
    CrossrefPubMedGoogle Scholar
  • 21 Zhu Y, Yang Y, Zhang Y. et al. Placental mesenchymal stem cells of fetal and maternal origins demonstrate different therapeutic potentials. Stem Cell Res Ther 2014; 5: 48
    CrossrefPubMedGoogle Scholar
  • 22 Du W, Li X, Chi Y. et al. VCAM-1+placenta chorionic villi-derived mesenchymal stem cells display potent pro-angiogenic activity. Stem Cell Res Ther 2016; 7: 49
    CrossrefPubMedGoogle Scholar
  • 23 Kong P, Xie X, Li F. et al. Placenta mesenchymal stem cell accelerates wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK) rats. Biochemical and Biophysical Research Communications 2013; 438: 410-419
    CrossrefPubMedGoogle Scholar
  • 24 Mareschi K, Castiglia S, Sanavio F. et al. Immunoregulatory effects on T lymphocytes by human mesenchymal stromal cells isolated from bone marrow, amniotic fluid, and placenta. Experimental Hematology 2016; 44: 138-150.e131
    CrossrefPubMedGoogle Scholar
  • 25 Zhang B, Adesanya TM, Zhang L. et al. Delivery of placenta-derived mesenchymal stem cells ameliorates ischemia induced limb injury by immunomodulation. Cell Physiol Biochem 2014; 34: 1998-2006
    CrossrefPubMedGoogle Scholar
  • 26 Gu YZ, Xue Q, Chen YJ. et al. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Human Immunology 2013; 74: 267-276
    CrossrefPubMedGoogle Scholar
  • 27 Jiang L, Dai Y, Cui F. et al. Expression of cytokines, growth factors and apoptosis-related signal molecules in chronic pressure ulcer wounds healing. Spinal Cord 2014; 52: 145-151
    CrossrefPubMedGoogle Scholar
  • 28 Brockmann L, Giannou AD, Gagliani N et al. Regulation of TH17 cells and associated cytokines in wound healing, tissue regeneration, and carcinogenesis. International journal of molecular sciences 2017; 18:
    PubMed
  • 29 Toan NL, Van Hoan N, Cuong DV. et al. Adipose tissue-derived cytokines and their correlations with clinical characteristics in Vietnamese patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 2018; 10: 41
    CrossrefPubMedGoogle Scholar
  • 30 Tong HV, Luu NK, Son HA. et al. Adiponectin and pro-inflammatory cytokines are modulated in Vietnamese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation 2017; 8: 295-305
    CrossrefPubMedGoogle Scholar
  • 31 Polina ER, da Silva Pereira BL, Crispim D. et al. Association of -1082A>G polymorphism in the interleukin-10 gene with estimated glomerular filtration rate in type 2 diabetes. Kidney & Blood Pressure Research 2017; 42: 1164-1174
    CrossrefPubMedGoogle Scholar
  • 32 Qiao YC, Shen J, He L. et al. Changes of regulatory t cells and of proinflammatory and immunosuppressive cytokines in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Journal of Diabetes Research 2016; 2016: 3694957
    PubMedGoogle Scholar